Retinopathy

Cavan D et al. Diabetes Res Clin Prac 2018; 143: 170–178. doi: 10.1016/j.diabres.2018.07.004

Krishnasamy S, Abell TL. Diabetes Ther (2018); 9 (Suppl 1): 1. doi: 10.1007/s13300-018-0454-9

Castellano-Guerrero AM et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1172-5

Musen G et al. Diabetes Care 2018: dc171955. doi: 10.2337/dc17-1955

Pease A et al. Cardiovasc Diabetol 2018; 17: 77. doi: 10.1186/s12933-018-0726-8

Ahola AJ, Forsblom C, Groop PH. Acta Diabetol 2018. doi: 10.1007/s00592-018-1159-2

Zivkovic M, Petrovski G, Bitoska I. Acta Diabetol 2018; Advance online publication. doi: 10.1007/s00592-018-1147-6

Itho H et al. Diabetes Care 2018; Advance online publication. doi: 10.2337/dc17-2224

The CLEOPATRA trial results show that wearing a mask that emits blue–green light during sleep does not reduce the progression of non-central diabetic macular edema.

Katayama S, Hatano M, Issiki M. Hypertens Res 2018; 41: 213–229. doi: 10.1038/s41440-017-0001-5

Yamazaki D, Hitomi H, Nishiyama A. Hypertens Res 2018; 41: 147–156. doi: 10.1038/s41440-017-0008-y

Researchers have developed a screening tool, the Liverpool Risk Calculation Engine, which offers individualized, variable-interval, risk-based screening for diabetic retinopathy and has sufficient performance for local introduction into practice, according to a modeling study.

Forbes JM, Fotheringham AK. Diabetologia 2017; 60: 2129–2138. doi: 10.1007/s00125-017-4360-x

Changes in the structure and pattern of the retinal vasculature are an early indicator of diabetic retinopathy, and improve the ability of established risk factors to predict which patients will develop it, say researchers.

Results of the CLARITY trial suggest that aflibercept treatment may produce better visual outcomes than laser photocoagulation in patients with proliferative diabetic retinopathy.

Individuals with diabetic macular edema or proliferative diabetic retinopathy are more likely to develop and die from cardiovascular disease than those without either condition, results of a systematic review and meta-analysis show.

A substantial proportion of diabetes patients experience improvements in diabetic retinopathy while receiving anti-vascular endothelial growth factor treatment, shows the latest analysis from DRCR.net.

Researchers have used DCCT/EDIC data to produce risk-based screening recommendations for retinopathy in patients with type 1 diabetes that reduce costs without delaying diagnosis.

Results of a US study suggest that implementation of a primary care-based teleretinal diabetic retinopathy screening program could improve access to screening and maximize efficiency.

A deep learning algorithm is highly accurate for the detection of diabetic retinopathy in retinal fundus photographs, researchers report in JAMA.